Colombia Pharmaceuticals and Healthcare Report Q1 2013
Business Monitor International, February 2013, Pages: 114
BMI View
Improvements in Colombia's pharmaceutical regulation system will expand local patients'
access to medicines. However, it will also put pricing pressures on drugmakers, and promote the use of generic versions, which will undermine the growth of patented drug market. Nevertheless, BMI expects more foreign pharmaceutical companies to invest in Colombia, capitalising on the country's strong longterm growth prospects.
Headline Expenditure Projections
- Pharmaceuticals: COP7,076bn (US$3.83bn) in 2011 to COP7,612bn (US$4.23bn) in 2012;
+7.6% in local currency terms and +10.4% in US dollar terms. Forecast broadly in line with Q412.
- Healthcare: COP29,953bn (US$16.21bn) in 2011 to COP31,557bn (US$17.53bn) in 2012;
+5.4% growth in local currency terms and +8.2% in US dollar terms. Forecast broadly in line with Q412.
- Medical devices: COP1,901bn (US$1.03bn) in 2011 to COP2,127bn (US$1.18bn) in 2012;
+11.9% growth in local currency terms and +14.9% in US dollar terms. Forecast broadly in line with Q412.
Executive Summary 7
SWOT Analysis 9
Colombia Pharmaceutical And Healthcare Industry SWOT 9
Colombia Political SWOT 10
Colombia Economic SWOT 10
Colombia Business Environment SWOT 11
Pharmaceutical Risk/Reward Ratings 12
Table: Americas Pharmaceutical Risk/Reward Ratings, Q113 12
Rewards 13
Risks 13
Colombia - Market Overview 15
Regulatory Regime 16
Other Regulatory Issues 17
Recent Regulatory Developments 18
Pharmaceutical Advertising 18
Intellectual Property Regime 19
Intellectual Property Shortcomings 21
Counterfeit Pharmaceuticals 22
Health-Related Litigation 24
Free Trade Agreement With The US 24
Table: Colombia-US FTA Mechanisms Relevant To Intellectual Property 25
Pricing Regime 25
Table: New Drug Pricing Classification by Type, 2005 26
Recent Pricing Regime Developments 27
Reimbursement Regime 28
National Drug Policy 30
Industry Developments 31
Epidemiology 31
HIV/AIDS 32
Healthcare Sector 33
Healthcare Insurance 34
Private Health Insurance 37
Healthcare Insurance Funding 37
Emergency Healthcare Reform 38
Medical Tourism 39
Research and Development (R&D) 39
Table: Pharmaceutical Research and Science Centre (CECIF) Members, 2012 40
Clinical Trials 41
Medical Devices 42
Industry Forecast Scenario 44
Pharmaceutical Market Forecast 44
Table: Pharmaceutical Sales, 2008-2016 44
Healthcare Market Forecast 46
Table: Overall Healthcare Expenditure, 2008-2016 48
Table: Government Healthcare Expenditure, 2008-2016 48
Table: Private Healthcare Expenditure, 2008-2016 49
Key Growth Factors - Macroeconomic 50
Prescription Drug Market Forecast 52
Table: Prescription Drug Sales, 2008-2016 53
Patented Drug Market Forecast 54
Table: Patented Drug Sales, 2008-2016 55
Generic Drug Market Forecast 56
Table: Generic Drug Sales, 2008-2016 57
OTC Medicine Market Forecast 58
Table: OTC Medicine Sales, 2008-2016 59
Pharmaceutical Trade Forecast 61
Table: Pharmaceutical Trade, 2009-2016 63
Medical Device Market Forecast 64
Table: Medical Device Sales, 2008-2016 64
Other Healthcare Data Forecasts 66
Key Risks To BMI's Forecast Scenario 66
Competitive Landscape 67
Pharmaceutical Industry 67
Table: Pharmaceutical Producers, 2000-2009 68
Table: Pharmaceutical Production, 2000-2009 68
Table: Pharmaceutical Personnel, 2000-2009 69
Domestic Pharmaceutical Sector 69
Foreign Pharmaceutical Sector 70
Table: Members Of Asociación De Laboratorios Farmacéuticos De Investigación (AFIDRO), 2012 70
Table: Leading Pharmaceutical Companies By Revenues, 2011 (COPmn) 71
Table: Leading Pharmaceutical Importers/Wholesalers By Revenues, 2011 73
Table: INVIMA-Certified Pharmaceutical Manufacturing Establishments, October 15 2010 74
Pharmaceutical Company Developments 80
Pharmaceutical Wholesale 81
Pharmaceutical Retail 82
Table: Leading Pharmaceutical Retailers, 2009-2010 83
Company Profiles 86
Local Companies 86
Tecnoquímicas 86
Lafrancol 89
Laboratorios Genfar SA 92
Laboratorios Bussié 94
Multinational Companies 96
GlaxoSmithKline 96
Pfizer 98
Merck & Co 00
Sanofi 02
Novartis 04
Demographic Outlook 105
Table: Population By Age Group, 1990-2020 ('000) 05
Table: Population By Age Group, 1990-2020 (% of total) 06
Table: Key Population Ratios, 1990-2020 07
Table: Rural And Urban Population, 1990-2020 07
Glossary 108
BMI Methodology 110
How We Generate Our Pharmaceutical Industry Forecasts 10
Pharmaceutical Risk/Reward Ratings Methodology 11
Ratings Overview 11
Table: Pharmaceutical Risk/Reward Indicators 12
Weighting 13
Table: Weighting Of Components 13
Sources 13
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
